Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas

NCT01231347 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT01231347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01231347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
NantCell, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 7, 2011
Completion date
December 12, 2012
Enrollment
800 (actual)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, advanced malignancy, advanced solid tumors, bone metastases, cancer, cancer of pancreas, cancer of the pancreas, endocrine cancer, metastases, metastatic cancer, metastatic pancreatic cancer, oncology, oncology patients, pancreas cancer, pancreatic cancer, solid tumors